[Influence on the prescription of antiepileptic drugs in Spain (2006-2017) after evaluations of committees or commissions]. / Influencia en la prescripcion de antiepilepticos en España (2006-2017) tras evaluaciones de comites o comisiones.

INTRODUCTION: The drug evaluation in a defined market becomes more important if we manage to objectify the impact of it on health care professionals. SUBJECTS AND METHODS: It has been collected all the information related to the autonomic committees of evaluation of drugs in a period of time (from April 2006 to May 2017) and in those who have produced reports related to the N3A therapeutic group (antiepileptics) and it has been measured the quantitative impact of their evaluations on the prescription habits of specialists in each of the autonomous communities and globally in Spain. RESULTS: The impact was measured by analyzing the sales data in units (IQVIA) by provinces and at national level of each product evaluated. CONCLUSIONS: The impact of the work carried out by the autonomous evaluation committees and by the therapeutic positioning reports in relation to the antiepileptic drugs has been practically non-existent or null. We consider from this forum the suitability or not to keep the investment of time, personnel and other resources in this type of approach.

TITLE: Influencia en la prescripcion de antiepilepticos en España (2006-2017) tras evaluaciones de comites o comisiones.Introduccion. La evaluacion de los medicamentos en un determinado mercado y entorno cobra una mayor importancia si se consigue objetivar el impacto que pueda producir en los profesionales sanitarios. Sujetos y metodos. Se ha recopilado toda la informacion relativa a los comites autonomicos de evaluacion de medicamentos en un periodo de tiempo definido (desde abril de 2006 a mayo de 2017), en los que se han elaborado informes de farmacos pertenecientes al grupo terapeutico N3A (antiepilepticos) y se ha determinado la repercusion en terminos cuantitativos de sus dictamenes sobre el habito de prescripcion de los especialistas en cada una de las comunidades autonomas y globalmente en España. Resultados. La repercusion se midio analizando los datos de ventas en unidades (IQVIA) por provincias y nacional de cada uno de los productos evaluados. Conclusiones. El impacto de los trabajos realizados tanto por los comites autonomicos de evaluacion como por los informes de posicionamiento terapeutico en lo relativo a los farmacos antiepilepticos ha sido practicamente inexistente o nulo. Nos planteamos la idoneidad o no de mantener la inversion de tiempo, personal y otros recursos en este tipo de estrategias.

Socio-occupational and employment profile of patients with epilepsy.

OBJECTIVE: Epilepsy has a significant impact on quality of life. Many studies have observed higher unemployment rates among patients with epilepsy. However, unemployment rates vary according to the clinical conditions, country, and group studied. METHODS: Between October 2007 and February 2008, we performed a cross-sectional multicenter epidemiological study to evaluate the socio-occupational and employment profiles of 872 adult patients with epilepsy followed in outpatient epilepsy clinics in Spain. RESULTS: Fifty-eight percent of the patients were employed at the time of the survey, 10.9% of the patients were unemployed, and 12.5% were occupationally incapacitated. CONCLUSION: Patients with epilepsy had employment rates similar to those of the general population, and slightly higher levels of unemployment. The main factors associated with unemployment and incapacity were the presence of refractory epilepsy, the occurrence of a seizure in the last 12 months, level of education, and polytherapy.

Síndrome de nevus azul (Blue rubber bleb nevus): reporte de un caso / Syndrome of nevus blue (blue bubber bleb nevus): report of a case

Síndrome de Blue Rubber Bleb Nevus o Síndrome de Bean, es una entidad clínica caracterizada por hemangiomas cutáneos y tumores vasculares del tracto gastrointestinal. Se describen lesiones de localización extra intestinal. Representa una causa infrecuente de hemorragia digestiva. Se presenta el caso de un paciente masculino de 19 años de edad con hemorragia digestiva, lesiones cutáneas y endoscópicas características de este síndrome

Síndrome de ogilvie a propósito de un caso / Ogilvies syndrome a purpose of a case

El síndrome de Ogilvie o pseudobstrucción aguda colónica, es caracterizado por una dilatación aguda del colón, en ausencia de obstrucción mecánica, cuya etiología es desconocida y se asocia a pacientes con edad avanzada y patologías médicas o quirúrgicas previas. La recidiva después de tratamiento médico es del20-50 por ciento. Este caso es un paciente masculino de 63 años de edad, con síndrome epiléptico focal criptogenético y síndrome de Ogilvie, quien presento dilatación aguda colónica sin evidencia de obstrucción mecánica, con respuesta al tratamiento médico

[Development of a questionnaire for the assessment and quantification of overweight and obesity related lifestyles]. / Desarrollo de un cuestionario para la valoración y cuantificación de los hábitos de vida relacionados con el sobrepeso y la obesidad.

INTRODUCTION: Lifestyle intervention is mandatory for obesity treatment. The aim of this study is to design a questionnaire to describe and quantify those behaviours more closely related to obesity in the Spanish obese population. METHODS AND PROCEDURES: An expert panel designed a preliminary 57 Liker-type item questionnaire, which was self-administered to 335 overweight patients (110 male, 225 female; age, 42 +/- 14 years; BMI, 32.6 +/- 3.7 kg/m2). After a subjacent dimensionality searching and item reducing first phase, a shrunk questionnaire of 24 items was then self-administered to 156 overweight patients (52 male, 104 female; age 42 +/- 12 years; BMI, 33.1 +/- 3.5 kg/m2); 56 of those patients were re-administered the questionnaire in order to provide test-retest information. RESULTS: Final questionnaire includes 22 items clustered in five dimensions: diet caloric intake, searching for psychological well-being eating, physical activity, healthy eating and alcohol intake. Proposed factorial structure is mostly reproduced in different samples and using different extraction methods: all dimensions but alcohol intake score alpha values > 0.75 for liability; test-retest stability is greater than 0.90 in all dimensions but alcohol intake; results for all validity tests performed (of construct, of content and discriminative) are highly satisfactory. CONCLUSION: Metrics study results (liability and validity) demonstrate that the proposed questionnaire provides an excellent tool to assess those lifestyles related to obesity control.

Absence of an interaction between ibuprofen and zaleplon.

The potential interaction between zaleplon and ibuprofen was studied. Healthy adult volunteers were given a dose of zaleplon 10 mg alone, a dose of ibuprofen 600 mg alone, or a dose of zaleplon 10 mg and a dose of ibuprofen 600 mg concomitantly in an open-label, randomized, three-period crossover study. There was a seven-day washout period between treatments. Venous blood samples were collected for pharmacokinetic analysis at various intervals up to 14 hours after drug administration. A total of 17 subjects (11 men and 6 women) completed the study. There were no significant differences between zaleplon monotherapy and combination therapy in mean +/- SD, of zaleplon clearance (CL) (2.80 +/- 0.72 versus 2.72 +/- 0.89 L/hr/kg, respectively), maximum plasma concentration (Cmax) (37.1 +/- 17.9 versus 39.8 +/- 20.0 ng/mL), or area under the concentration-versus-time curve (AUC) (56.7 +/- 22.8 versus 59.2 +/- 22.0 ng.hr/mL). There were no significant differences between ibuprofen monotherapy and combination therapy in ibuprofen CL (71.6 +/- 17.0 versus 71.7 +/- 14.9 L/hr/kg), Cmax (40.8 +/- 10.2 versus 40.4 +/- 10.0 micrograms/mL), or AUC (127.6 +/- 29.6 versus 126.4 +/- 29.7 micrograms.hr/mL). Three subjects had one or more adverse effects with zaleplon alone, one subject had one or more with ibuprofen alone, and one subject had one or more with combination therapy. The adverse effects were mild and resolved without intervention. There was no evidence of a significant interaction between zaleplon and ibuprofen.

Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.

Serum bactericidal activity against a penicillin-susceptible strain and a penicillin-resistant strain of Streptococcus pneumoniae (amoxicillin and cefotaxime MICs, 0.001 and 1 microg/ml, respectively, and MBCs, 0.01 and 2 microg/ml, respectively) was measured in 12 healthy volunteers who each received an oral 875-mg dose of amoxicillin and an intramuscular 1-g dose of cefotaxime in a crossover fashion. The areas under the bactericidal activity-time curves for the two strains were found to be similar for both antibiotics despite the significantly higher (P < 0.002) AUC/MIC and peak level/MIC values for cefotaxime.

Nimodipine transfer into human breast milk and cerebrospinal fluid.

OBJECTIVE: To report nimodipine concentrations in breast milk and cerebrospinal fluid (CSF) of a lactating woman who was given the drug to prevent a vascular spasm secondary to angiographic examination. METHODS: A 36-year-old woman received a total dose of nimodipine 46 mg iv over 24 hours. She extracted milk when she noted mammary tightness, and blood samples were taken simultaneously by venipuncture in the arm contralateral to that of the nimodipine infusion. A CSF sample also was taken in a diagnostic lumbar puncture. RESULTS: Nimodipine concentration in milk was much lower than that in serum, with a milk/serum ratio of 0.06-0.15. The CSF/serum ratio was 0.01. We estimate that the infant would have received between 0.008% and 0.092% of the weight-adjusted dose that was administered to the mother if the baby had been nursed. CONCLUSIONS: Nimodipine is transferred to human milk in a lower proportion than are other calcium-channel blockers. These results suggest that treating the mother with nimodipine would entail no risk to the nursing infant.